Previous 10 | Next 10 |
NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full ...
NetworkNewsWire Editorial Coverage : Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs u...
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer R...
TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclin...
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offeri...
Genprex (NASDAQ: GNPX ): FY GAAP EPS of -$0.90. More news on: Genprex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on...
New York, New York--(Newsfile Corp. - March 29, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio publication titled, " Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy ." To hear the NetworkNewsWire Audio version, visit: ...
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “ Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy .” To hear th...
New York, New York--(Newsfile Corp. - March 28, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled ...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...